LobSor Pharmaceuticals

LobSor Pharmaceuticals
Om oss
Dela:
Prenumerera:

Om oss

Lobsor Pharmaceuticals is a privately held company based in Uppsala, Sweden founded late 2013. It is a fully owned subsidiary to Lobsor Holding AB. The founders of Lobsor, Ulf Rosén and Roger Bolsöy, have substantial previous experience from the treatment of Parkinson’s disease in advanced stages especially continuous infusion of levodopa into the small intestine via a pump. Based on their own experience, and in close liaison with leading neurologists and patient organizations expressing and formulating areas of therapy improvements, the Lecigon treatment system has been developed with the aim to, in several aspects, improve daily living for individuals affected by progressive Parkinson’s disease and suitable for an invasive treatment.

Länkar

Lobsor Pharmaceuticals corporate website

Välj datumintervall -

Taggar ( valda)

Alla Regulatorisk Icke regulatorisk

Lobsor Pharmaceuticals receive approval for Lecigon in Germany, the Netherlands, Belgium, Austria, Slovenia and Romania

tor, sep 17, 2020 14:37 CET

Uppsala, September 17, 2020. Lobsor Pharmaceuticals AB today announced that Lecigon, a treatment system for Parkinson’s disease has been approved (the MPA, Swedish Medical Products Agency has confirmed End of Procedure) according to the European Mutual Recognition Procedure (MRP) in Germany, the Netherlands, Belgium, Austria, Slovenia and Romania. This follows the marketing authorization for Lecigon granted in Sweden in 2018 as well as Denmark, Finland and Norway in 2019. Immediately after the MRP Approval, the procedure enters a national phase for approval of labels, package inserts etc. in

Det finns inga träffar som matchar nuvarande filter

Det finns inga fler träffar som matchar nuvarande filter

Tillbaka till sidans topp

Media